<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119674</url>
  </required_header>
  <id_info>
    <org_study_id>GBM-AS</org_study_id>
    <nct_id>NCT04119674</nct_id>
  </id_info>
  <brief_title>Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma</brief_title>
  <official_title>Pilot Study of Anlotinib in Combination With STUPP Regimen for Treatment of Patients With Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the the efficacy and safety of Anlotinib in combination
      with STUPP regimen for patients with newly diagnosed glioblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>from enrollment to progression or death (for any reason),assessed up to 18months</time_frame>
    <description>Progression-Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Adverse events are described in terms of CTC AE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Health-related quality of life are measured by the EORTC-QL30/BN20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Neurocognitive function are measured by John-Hopkins adapted cognitive exam (ACE).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: arm Biological: Anlotinib Drug: Temozolomide Radiotherapy:2.0 Gy/fraction ×30 fractions Monday to Friday total dose of 60Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib With STUPP Regimen</description>
    <arm_group_label>Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide Capsule</intervention_name>
    <description>Anlotinib With STUPP Regimen</description>
    <arm_group_label>Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Histologically proven diagnosis of glioblastoma (WHO grade IV) 2.1.4-6 weeks after
        surgery and incision has healed 3.Patients with quantifiable target lesions according to
        RANO criteria 4.Aged 18-70 years 5.Karnofsky performance status ≥ 60 6.Corticosteroids
        doses has been stabilized or decreased within 5 days 7.No previous radiotherapy,
        chemotherapy, immunotherapy or biotherapy 8.Adequate bone marrow function: Hemoglobin ≥
        100g/L，Platelets ≥ 80×109/L，Absolute neutrophil count (ANC) ≥ 1.5×109/L 9.Adequate renal
        function: Serum creatinine ≤ 1.25 x UNL (upper normal limit) or creatinine clearance ≥ 60
        ml/min 10.Adequate hepatic function: serum bilirubin ≤ 1.5 x UNL, AST and ALT ≤ 2.5 x
        UNL，ALP≤5x UNL 11.Adequate coagulation function: PT ≤ 5 seconds above the UNL， APTT≤ 5
        seconds above the UNL 12.For females of child-bearing potential, negative serum pregnancy
        test within 14 days prior to registration. Women of childbearing potential and male
        participants must practice adequate contraception during participation in the study and
        within 8 weeks after the last administration of the drug 13.Subject is willing and able to
        comply with the protocol for the duration of the study including undergoing treatment and
        scheduled visits and examinations including follow up 14.Able to provide written informed
        consent

        Exclusion Criteria:

          1. Recurrent malignant gliomas

          2. Prior invasive malignancy (except for non-melanomatous skin cancer or carcinoma in
             situ of cervix)

          3. Contraindication of radiotherapy and chemotherapy defined as follows: Acute bacterial
             or fungal infection，Unstable angina and/or congestive heart failure within the last 6
             months，co-morbidity with immunosuppressive therapy

          4. Pregnant or lactating women

          5. women of childbearing potential and men who are sexually active and not willing/able
             to use medically acceptable forms of contraception

          6. Evidence of bleeding diathesis or coagulopathy

          7. Patients on anticoagulants for co-morbidity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Ming</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Yuanyuan, MD</last_name>
    <phone>08613738103808</phone>
    <email>chenyy@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang cancer hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Ming, MD</last_name>
      <phone>0086-571-88122068</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 6, 2019</study_first_submitted>
  <study_first_submitted_qc>October 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 6, 2019</last_update_submitted>
  <last_update_submitted_qc>October 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

